Top

Published in:

Open Access 01-05-2019 | Amlodipine

Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review

Authors: Rabia Johnson, Phiwayinkosi Dludla, Sihle Mabhida, Mongi Benjeddou, Johan Louw, Faghri February

Published in: Heart Failure Reviews | Issue 3/2019

Abstract

Blood pressure (BP) is a complex trait that is regulated by multiple physiological pathways and include but is not limited to extracellular fluid volume homeostasis, cardiac contractility, and vascular tone through renal, neural, or endocrine systems. Uncontrolled hypertension (HTN) has been associated with an increased mortality risk. Therefore, understanding the genetics that underpins and influence BP regulation will have a major impact on public health. Moreover, uncontrolled HTN has been linked to inter-individual variation in the drugs’ response and this has been associated with an individual’s genetics architecture. However, the identification of candidate genes that underpin the genetic basis of HTN remains a major challenge. To date, few variants associated with inter-individual BP regulation have been identified and replicated. Research in this field has accelerated over the past 5 years as a direct result of on-going genome-wide association studies (GWAS) and the progress in the identification of rare gene variants and mutations, epigenetic markers, and the regulatory pathways involved in the pathophysiology of BP. In this review we describe and enhance our current understanding of how genetic variants account for the observed variability in BP response in patients on first-line antihypertensive drugs, amlodipine and hydrochlorothiazide.

Papathanasiou G, Zerva E, Zacharis I, Papandreou M, Papageorgiou E, Tzima C, Georgakopoulos D, Evangelou A (2015) Association of high blood pressure with body mass index, smoking and physical activity in healthy young adults. Open Cardiovasc Med J 9:5–17CrossRefPubMedPubMedCentral

Shirley M, McCormack PL (2015) Perindopril/amlodipine (Prestalia(®)): a review in hypertension. Am J Cardiovasc Drugs 15:363–370CrossRefPubMed

Seedat YK (2015) Why is control of hypertension in sub-Saharan Africa poor? Cardiovasc J Afr 26:193–195CrossRefPubMedPubMedCentral

Adeniyi, O.V.; Yogeswaran, P.; Longo-Mbenza, B.; Ter Goon, D. Uncontrolled hypertension and its determinants in patients with concomitant type 2 diabetes mellitus (T2DM) in rural South Africa. PLoS One 2016, 11, e0150033

Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP (2015) Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension (65):291–298

Sethi BK, Baruah MP, Kumar AS (2017) Blood pressure variability in patients with diabetes mellitus with hypertension: treatment recommendations and role of amlodipine. J Assoc Physicians India 65:67–71PubMed

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520CrossRef

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120:713–719CrossRefPubMed

Gupta AK, Arshad S, Poulter NR (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension (55):399–407

10.

Gradman AH, Basile JN, Carter BL, Bakris GL (2011) Combination therapy in hypertension. J Clin Hypertens 13:146–154CrossRef

11.

Destro M, Cagnoni F, D'Ospina A, Ricci AR, Demichele E, Peros E, Zaninelli A, Preti P (2010) Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Vasc Health Risk Manag 6:253–260CrossRefPubMedPubMedCentral

12.

Levi-Marpillat N, Macquin-Mavier I, Tropeano AI, Parati G, Maison P (2014) Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res 37:585–590CrossRefPubMed

13.

Ushigome E, Fukui M, Hamaguchi M, Tanaka T, Atsuta H, Ohnishi M, Oda Y, Yamazaki M, Hasegawa G, Nakamura N (2013) Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes. J Diabetes Investig 4:399–404CrossRefPubMedPubMedCentral

14.

Webb, A.J.; Fischer, U.; Mehta, Z.; Rothwell, P.M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010, 375, 906–915

15.

Harman J, Walker ER, Charbonneau V, Akylbekova EL, Nelson C, Wyatt SB (2013) Treatment of hypertension among African Americans: the Jackson Heart Study. J Clin Hypertens 15:367–374CrossRef

16.

Gudmundsdottir H, Hoieggen A, Stenehjem A, Waldum B, Os I (2012) Hypertension in women: latest findings and clinical implications. Ther Adv Chronic Dis 3:137–146CrossRefPubMedPubMedCentral

17.

Schmieder RE, Bohm M (2011) Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens 25:354–363CrossRefPubMed

18.

Thomopoulos C, Skalis G, Makris T (2015) Resistant hypertension: a real entity of a phantom diagnosis. J Clin Hypertens 17:578–579CrossRef

19.

Fares H, DiNicolantonio JJ, O'Keefe JH, Lavie CJ (2016) Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart 3:e000473CrossRefPubMedPubMedCentral

20.

Lee HY, Kang HJ, Koo BK, Oh BH, Heung-Sun K, Kim KS, Seo HS, Ro YM, Kang JH, Woong CJ et al (2005) Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. Clin Ther 27:728–739CrossRefPubMed

21.

Julius S (1988) Amlodipine in hypertension: an overview of the clinical dossier. J Cardiovasc Pharmacol 12(Suppl 7):S27–S33CrossRefPubMed

22.

Zhu Y, Wang F, Li Q, Zhu M, Du A, Tang W, Chen W (2014) Amlodipine metabolism in human liver microsomes and roles of cyp3a4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos 42:245–249CrossRefPubMed

23.

Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 22:21–25CrossRefPubMedPubMedCentral

24.

Abernethy DR (1992) Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 80(Suppl 1):31–36CrossRefPubMed

25.

Beresford AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA (1988) Metabolism and kinetics of amlodipine in man. Xenobiotica 18:245–254CrossRefPubMed

26.

Murdoch D, Heel RC (1991) Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 41:478–505CrossRefPubMed

27.

Meredith PA, Elliott HL (1992) Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 22:22–31CrossRefPubMed

28.

Carter BL, Ernst ME, Cohen JD (2004) Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 1979(43):4–9CrossRef

29.

Salvetti A, Ghiadoni L (2006) Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 17:S25–S29CrossRefPubMed

30.

Lund BC, Ernst ME (2012) The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans. J Clin Hypertes 14:623–629CrossRef

31.

Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E (2005) Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 18:1077–1083CrossRefPubMed

32.

Ellison DH, Loffing J (2009) Thiazide effects and adverse effects: insights from molecular genetics. Hypertension 1979(54):196–202CrossRef

33.

Beermann B, Groschinsky-Grind M (1977) Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12:297–303CrossRefPubMed

34.

Patel RB, Patel UR, Rogge MC, Shah VP, Prasad VK, Selen A, Welling PG (1984) Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 73:359–361CrossRefPubMed

35.

Beermann B, Groschinsky-Grind M (1978) Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. Eur J Clin Pharmacol 13:125–128CrossRefPubMed

36.

Beermann B, Groschinsky-Grind M, Rosen A (1976) Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther 19:531–537CrossRefPubMed

37.

Yamazaki M, Itoh S, Okuda T, Tanabe K, Nakahama H, Fukuhara Y, Orita Y (1989) Binding of hydrochlorothiazide to erythrocytes. Aust J Pharm 12:423–428

38.

Deventer K, Pozo OJ, Van Eenoo P, Delbeke FT (2009) Detection of urinary markers for thiazide diuretics after oral administration of hydrochlorothiazide and altizide-relevance to doping control analysis. J Chromatogr A 1216:2466–2473CrossRefPubMed

39.

Okuda T, Itoh S, Yamazaki M, Nakahama H, Fukuhara Y, Orita Y (1987) Biopharmaceutical studies of thiazide diuretics. Iii. In vivo formation of 2-amino-4-chloro-m-benzenedisulfonamide as a metabolite of hydrochlorothiazide in a patient. Chem Pharm Bull 35:3516–3518CrossRefPubMed

40.

Zuo XC, Zhang WL, Yuan H, Barrett JS, Hua Y, Huang ZJ, Zhou HH, Pei Q, Guo CX, Wang JL et al (2014) Abcb1 polymorphism and gender affect the pharmacokinetics of amlodipine in chinese patients with essential hypertension: a population analysis. Drug Metab Pharmacokinet 29:305–311CrossRefPubMed

41.

Kim KA, Park PW, Park JY (2007) Effect of abcb1 (mdr1) haplotypes derived from g2677t/c3435t on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 63:53–58CrossRefPubMed

42.

Guo C, Pei QI, Tan H, Huang Z, Yuan H, Yang G (2015) Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients. Biomed Rep 3:195–200CrossRefPubMed

43.

Kamide K, Yang J, Matayoshi T, Takiuchi S, Horio T, Yoshii M, Miwa Y, Yasuda H, Yoshihara F, Nakamura S et al (2009) Genetic polymorphisms of l-type calcium channel alpha1c and alpha1d subunit genes are associated with sensitivity to the antihypertensive effects of l-type dihydropyridine calcium-channel blockers. Circ J 73:732–740CrossRefPubMed

44.

Kamide K, Asayama K, Katsuya T, Ohkubo T, Hirose T, Inoue R, Metoki H, Kikuya M, Obara T, Hanada H et al (2013) Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the homed-bp study. Pharmacogenomics 14:1709–1721CrossRefPubMed

45.

Bremer T, Man A, Kask K, Diamond C (2006) Cacna1c polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 7:271–279CrossRefPubMed

46.

Bhatnagar V, Garcia EP, O’Connor DT, Brophy VH, Alcaraz J, Richard E, Bakris GL, Middleton JP, Norris KC, Wright J (2010) Cyp3a4 and cyp3a5 polymorphisms and blood pressure response to amlodipine among african-american men and women with early hypertensive renal disease. Am J Nephrol 31:95–103

47.

Zhang YP, Zuo XC, Huang ZJ, Cai JJ, Wen J, Duan DD, Yuan H (2014) Cyp3a5 polymorphism, amlodipine and hypertension. J Hum Hypertens 28:145–149CrossRefPubMed

48.

Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY (2006) Effect of cyp3a5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy korean subjects. Clin Pharmacol Ther 80:646–656CrossRefPubMed

49.

Huang Y, Wen G, Lu Y, Wen J, Ji Y, Xing X, Li Y, Wen J, Yuan H (2017) Cyp3a4*1g and cyp3a5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. Int J Clin Pharmacol Ther 55:109–118

50.

Zhang ZL, Li HL, Wen ZP, Yang GP, Zhang W, Chen XP (2016) Influence of g-protein beta-polypeptide 3 c825t polymorphism on antihypertensive response to telmisartan and amlodipine in chinese patients. Chin Med J 129:8–14CrossRefPubMedPubMedCentral

51.

Cai J, Huang Z, Yang G, Cheng K, Ye Q, Ming Y, Zuo X, Zhou P, Yuan H (2011) Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. Am J Cardiovasc Drugs 11:401–409CrossRefPubMed

52.

Sorensen IF, Vazquez AI, Irvin MR, Sorensen P, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Arnett DK (2014) Pharmacogenetic effects of ‘candidate gene complexes’ on stroke in the genhat study. Pharmacogenet Genomics 24:556–563CrossRefPubMedPubMedCentral

53.

Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK (2008) Pharmacogenetic association of the nppa t2238c genetic variant with cardiovascular disease outcomes in patients with hypertension. Jama 299:296–307CrossRefPubMed

54.

Lynch AI, Irvin MR, Boerwinkle E, Davis BR, Vaughan LK, Ford CE, Aissani B, Eckfeldt JH, Arnett DK, Shrestha S (2013) Ryr3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Pharm J 13:330–334

55.

Choi HD, Suh JH, Lee JY, Bae SK, Kang HE, Lee MG, Shin WG (2013) Effects of ace and add1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis. Int J Clin Pharmacol Ther 51:718–724CrossRefPubMed

56.

Beeks E, van der Klauw MM, Kroon AA, Spiering W, Fuss-Lejeune MJ, de Leeuw PW (2004) Alpha-adducin gly460trp polymorphism and renal hemodynamics in essential hypertension. Hypertension 1979(44):419–423CrossRef

57.

Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M et al (1997) Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349:1353–1357CrossRefPubMed

58.

Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, Zagato L, Delli Carpini S, Tantardini C, Brioni E et al (2008) Physiological interaction between alpha-adducin and wnk1-nedd4l pathways on sodium-related blood pressure regulation. Hypertnsion 1979(52):366–372CrossRef

59.

Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2005) Wnk1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 46:758–765CrossRefPubMed

60.

Russo CJ, Melista E, Cui J, De Stefano AL, Bakris GL, Manolis AJ, Gavras H, Baldwin CT (2005) Association of nedd4l ubiquitin ligase with essential hypertension. Hypertension (46):488–491

61.

Newhouse SJ, Wallace C, Dobson R, Mein C, Pembroke J, Farrall M, Clayton D, Brown M, Samani N, Dominiczak A et al (2005) Haplotypes of the wnk1 gene associate with blood pressure variation in a severely hypertensive population from the british genetics of hypertension study. Hum Mol Genet 14:1805–1814CrossRefPubMed

62.

Kokubo Y, Kamide K, Inamoto N, Tanaka C, Banno M, Takiuchi S, Kawano Y, Tomoike H, Miyata T (2004) Identification of 108 snps in tsc, wnk1, and wnk4 and their association with hypertension in a japanese general population. J Hum Genet 49:507–515CrossRefPubMed

63.

Fava C, von Wowern F, Berglund G, Carlson J, Hedblad B, Rosberg L, Burri P, Almgren P, Melander O (2006) 24-h ambulatory blood pressure is linked to chromosome 18q21-22 and genetic variation of nedd4l associates with cross-sectional and longitudinal blood pressure in swedes. Kidney Int 70:562–569CrossRefPubMed

64.

Tobin MD, Raleigh SM, Newhouse S, Braund P, Bodycote C, Ogleby J, Cross D, Gracey J, Hayes S, Smith T et al (2005) Association of wnk1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 112:3423–3429CrossRefPubMed

65.

Nakajima T, Wooding S, Sakagami T, Emi M, Tokunaga K, Tamiya G, Ishigami T, Umemura S, Munkhbat B, Jin F et al (2004) Natural selection and population history in the human angiotensinogen gene (agt): 736 complete agt sequences in chromosomes from around the world. Am J Hum Genet 74:898–916CrossRefPubMedPubMedCentral

66.

Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2004) Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharm J 4:17–23

67.

Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, Gums JG, Gong Y, Cooper-DeHoff RM, Frau F et al (2015) Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc e001521:4

68.

Vasiliou V, Pappa A, Estey T (2004) Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 36:279–299CrossRefPubMed

69.

Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga D, Piras DA et al (2015) Tet2 and csmd1 genes affect sbp response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens 33:1301–1309CrossRefPubMedPubMedCentral

70.

Tavasoli M, Li L, Al-Momany A, Zhu LF, Adam BA, Wang Z, Ballermann BJ (2016) The chloride intracellular channel 5a stimulates podocyte rac1, protecting against hypertension-induced glomerular injury. Kidney Int 89:833–847CrossRefPubMed

71.

Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-Dehoff RM et al (2012) Effects of genetic variation in h3k79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med 10:56CrossRefPubMedPubMedCentral

72.

Salvi E, Wang Z, Rizzi F, Gong Y, McDonough CW, Padmanabhan S, Hiltunen TP, Lanzani C, Zaninello R, Chittani M et al (2017) Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide. THypertension (69):51–59

73.

Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ et al (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478:103–109CrossRefPubMed

74.

Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, Beitelshees AL, Chapman AB, Gums JG, Bailey KR et al (2012) Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet 5:686–691CrossRefPubMedPubMedCentral

75.

Vandell AG, McDonough CW, Gong Y, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Johnson RJ et al (2014) Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study. J Intern Med 276:486–497CrossRefPubMedPubMedCentral

76.

Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG et al (2013) Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 1979(62):391–397CrossRef

77.

Sa ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB et al (2018) Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genet 11:55

78.

Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-Dehoff RM, Boerwinkle E, Johnson JA, Bailey KR (2012) Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med 10:47CrossRefPubMedPubMedCentral

79.

Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Del-Aguila JL et al (2013) Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharm J 13:430–436

80.

Gamba G, Saltzberg SN, Lombardi M, Miyanoshita A, Lytton J, Hediger MA, Brenner BM, Hebert SC (1993) Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter. Proc Natl Acad Sci U S A 90:2749–2753CrossRefPubMedPubMedCentral

81.

Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL et al (2009) Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 157:442–449CrossRefPubMedPubMedCentral

82.

Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, Hedner T, Melander O (2011) A functional variant of the nedd4l gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens 29:388–395CrossRefPubMed

83.

Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414–417CrossRefPubMedPubMedCentral

84.

Johnsen DD, Kacimi R, Anderson BE, Thomas TA, Said S, Gerdes AM (2005) Protein kinase c isozymes in hypertension and hypertrophy: insight from shhf rat hearts. Mol Cell Biochem 270:63–69CrossRefPubMed

85.

Donner KM, Hiltunen TP, Hannila-Handelberg T, Suonsyrja T, Kontula K (2012) STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men. Hypertens Res 35:107–114CrossRefPubMed

86.

Wang Y, O'Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, Shi X, Pan L, Rampersaud E, Shen H et al (2009) From the cover: whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A 106:226–231CrossRefPubMed

87.

Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, Langaee TY, Beitelshees AL, Cooper-Dehoff RM et al (2013) Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharm J 13:257–263

88.

Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, Sicotte H, Kocher JP, Rodin AS, Boerwinkle E (2008) Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (52):359–365

89.

Fleckenstein A (1983) History of calcium antagonists. Circ Res 52:13–16

90.

Eisenberg MJ, Brox A, Bestawros AN (2004) Calcium channel blockers: an update. Am J Med 116:35–43CrossRefPubMed

91.

Johnson JA (2012) Advancing management of hypertension through pharmacogenomics. Ann Med 44(Suppl 1):S17–S22CrossRefPubMedPubMedCentral

92.

Konoshita T (2011) Do genetic variants of the renin-angiotensin system predict blood pressure response to renin-angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the renin-angiotensin system. Curr Hypertens Rep 13:356–361CrossRefPubMedPubMedCentral

93.

Lu Y, Zhong H, Tang Q, Huang Z, Jing N, Smith J, Miao R, Li Y, Yuan H (2017) Construction and verification of cyp3a5 gene polymorphisms using a saccharomyces cerevisiae expression system to predict drug metabolism. Mol Med Rep 15:1593–1600

94.

Bochud M, Bovet P, Burnier M, Eap CB (2009) Cyp3a5 and abcb1 genes and hypertension. Pharmacogenomics 10:477–487CrossRefPubMed

95.

Eichelbaum M, Fromm MF, Schwab M (2004) Clinical aspects of the mdr1 (abcb1) gene polymorphism. Ther Drug Monit 26:180–185CrossRefPubMed

96.

Fujiwara T, Nishimura T, Ohkuko T, Imai Y (2002) Rationale and design of homed-bp study: hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 7:77–82CrossRefPubMed

97.

Singh S, McDonough CW, Gong Y, Alghamdi WA, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B et al (2018) Genome wide association study identifies the hmgcs2 locus to be associated with chlorthalidone induced glucose increase in hypertensive patients. J Am Heart Assoc:7

98.

Neff KM, Nawarskas JJ (2010) Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev 18:51–56CrossRefPubMed

99.

Chapman AB, Schwartz GL, Boerwinkle E, Turner ST (2002) Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 61:1047–1055CrossRefPubMed

100.

Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H, Zhou J, Lashley K, Chen Y, Christman M et al (2009) A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet e1000564:5

101.

Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K et al (2011) Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east asians. Nat Genet 43:531–538CrossRefPubMedPubMedCentral

102.

Speirs HJ, Katyk K, Kumar NN, Benjafield AV, Wang WY, Morris BJ (2004) Association of g-protein-coupled receptor kinase 4 haplotypes, but not hsd3b1 or ptp1b polymorphisms, with essential hypertension. J Hypertens 22:931–936CrossRefPubMed

103.

Tripodi G, Citterio L, Kouznetsova T, Lanzani C, Florio M, Modica R, Messaggio E, Hamlyn JM, Zagato L, Bianchi G et al (2009) Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. Am J Hypertens 22:357–363CrossRefPubMedPubMedCentral

104.

Shimodaira M, Nakayama T, Sato N, Aoi N, Sato M, Izumi Y, Soma M, Matsumoto K (2010) Association of hsd3b1 and hsd3b2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure. Eur J Endocrinol 163:671–680CrossRefPubMed

105.

Rosmond R, Chagnon M, Bouchard C, Bjorntorp P (2002) Polymorphism in exon 4 of the human 3 beta-hydroxysteroid dehydrogenase type i gene (hsd3b1) and blood pressure. Biochem Biophys Res Commun 293:629–632CrossRefPubMed

106.

Ritchie MD (2012) The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-gwas era. Hum Genet 131:1615–1626CrossRefPubMedPubMedCentral

107.

Arwood MJ, Cavallari LH, Duarte JD (2015) Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep 17:586CrossRefPubMedPubMedCentral

108.

International HapMap Consortium (2003) The International HapMap Project. Nature 426(6968):789–96

109.

Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. Current Protocols Human Genetics Unit 7.20

Title: Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review
Authors: Rabia Johnson
Phiwayinkosi Dludla
Sihle Mabhida
Mongi Benjeddou
Johan Louw
Faghri February
Publication date: 01-05-2019
Publisher: Springer US
Keywords: Amlodipine
Hydrochlorothiazide
Hypertension
Hypertension
Published in: Heart Failure Reviews / Issue 3/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-09765-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Protective role of beta-blockers in chemotherapy-induced cardiotoxicity—a systematic review and meta-analysis of carvedilol

Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

Left ventricular noncompaction, morphological, and clinical features for an integrated diagnosis

Comparison of survival for cardiac resynchronization therapy in atrial fibrillation patients with or without atrio-ventricular junction ablation and patients in sinus rhythm: a systematic review and network meta-analysis

Obesity and heart failure with preserved ejection fraction: a paradox or something else?

Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page